A magazine for friends of the Warren Alpert Medical School of Brown University.

Brown Launches Center for Alzheimer’s Disease Research


With $30 million in support, the center aims to accelerate the pace of development for novel treatments and cures.

With support from two generous gifts totaling $30 million, Brown University is establishing a new Center for Alzheimer’s Disease Research with the aim of building a world-class research program focused on early detection and treatment of Alzheimer’s disease and related dementias.

The center will integrate the expertise of scientists and physicians at Brown’s Robert J. and Nancy D. Carney Institute for Brain Science and the Division of Biology and Medicine, home to the Warren Alpert Medical School. Its launch is made possible by gifts of $25 million and $5 million from donors who wish to remain anonymous.

University leaders say the center will build on Brown’s existing strengths in Alzheimer’s disease research, which range from the study of risk genes, cognition, and the biology of aging to development of new therapeutics and care of patients with dementia. By linking together scientific and clinical work across these areas, the center will create a uniquely interconnected program with the goal of breakthroughs that change the trajectory of Alzheimer’s disease and related dementias.

Brown President Christina H. Paxson says that with the devastating consequences of Alzheimer’s disease and dementia impacting more families every year, the University will bring the full force of its scholars’ medical and brain science expertise to expedite progress toward new treatments. With faculty research fueled by federal funding, Brown ranks among the top 20 universities in the nation for research on the disease.

“This is truly a transformative moment for Alzheimer’s disease and dementia research at Brown,” Paxson says. “We have a robust foundation in place, and by bringing aboard new scholars, investing in facilities, and creating the infrastructure to connect the incredible work already happening in our labs and clinical settings, our goal is to accelerate development toward novel treatments and cures in the fight against this devastating disorder.”

Continue reading.


Comments are closed.